论文部分内容阅读
目的 :采用以大剂量环磷酰胺(HD CTX)主为联合化疗方案治疗由恶性肿瘤引起的上腔静脉综合征(SVCS)。方法 :SVCS32例 ,其中肺癌与胸腺癌15例选用CAP方案 ,恶性淋巴瘤6例选用ABCOP方案。结果 :恶性淋巴瘤CR66.67%(4/6) ,PR33.33%(2/6)。SCLCCR28.57%(4/14) ,PR35.71 %(5/14) ,NC28.57%(4/14) ,PD7.14%(1/14)。NSCLSCR9 %(1/11) ,PR36.36 %(4/11) ,NC36.36%(4/11) ,PD18.18%(2/11)。胸腺癌1例为NC。SVCS2天内缓解21.9%(7/32) ,3～5天缓解43.8%(14/32) ,5～7天缓解18.8%(6/32) ,7天以上缓解15.6 %(5/32) ,1周内危象缓解84.5%(26/32)。结论 :HD CTX治疗SVCS缓解率高 ,疗效确切 ,副作用可耐受。
OBJECTIVE: To treat patients with superior vena cava syndrome (SVCS) caused by malignant tumor by using high dose cyclophosphamide (HDCTX) combined with chemotherapy. Methods: Thirty-two cases of SVCS were selected, among which 15 cases of lung cancer and thymus cancer were selected as CAP regimen and 6 cases of malignant lymphoma were selected as ABCOP regimen. Results: Malignant lymphoma CR66.67% (4/6), PR33.33% (2/6). SCLCCR28.57% (4/14), PR35.71% (5/14), NC28.57% (4/14) and PD7.14% (1/14). NSCLSCR 9% (1/11), PR 36.36% (4/11), NC 36.36% (4/11), PD 18.18% (2/11). One case of thymoma was NC. In SVCS, 21.9% (7/32) were relieved in 2 days, 43.8% (3/32) in 3-5 days, 18.8% (6/32) in 5-7 days, 15.6% (5/32) in 1 ~ Weekly crisis relief 84.5% (26/32). Conclusion: HDCTX treatment SVCS high response rate, the exact effect, side effects can be tolerated.